Changes after publication

Changes after publication

February 2014: implementation section updated to clarify that tocilizumab is recommended as an option for treating rheumatoid arthritis. Additional minor maintenance update also carried out.

June 2012: minor maintenance

January 2016: The first bullet point of recommendation 1.1 has been updated by the recommendations in the NICE technology appraisal guidance on adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.

  • National Institute for Health and Care Excellence (NICE)